Somatropin

Subcutaneous
Children with short stature homeobox-containing (SHOX) deficiency

Subcutaneous
Growth retardation due to chronic renal insufficiency, Turner's syndrome

Subcutaneous
Growth retardation in children who were born small for gestational age, Prader-Will syndrome

Subcutaneous
Growth hormone deficiency

Subcutaneous
Short bowel syndrome

Subcutaneous
HIV-associated wasting or cachexia

Acute critical illness due to heart or abdominal surgery, multiple accidental trauma or respiratory failure; active neoplasms, proliferative or preproliferative diabetic retinopathy; lactation; patients with closed epiphyses. Intracranial lesions. Patients with Prader-Willi syndrome who are severely obese or have severe respiratory impairment.

Monitor thyroid function; benign intracranial hypertension. DM; may require dose reduction in insulin. Pregnancy. Discontinue treatment if there is evidence of tumour growth. Monitoring in patients with scoliosis is recommended due to risk of progression of scoliosis.

Hypothyroidism, peripheral oedema; headache; muscle and joint pain; benign intracranial hypertension. Loss of glycaemic control in diabetics.

Parenteral/SC: C

High doses of corticosteroid may inhibit growth-promoting effects of somatropin.

Description: Somatropin is a synthetic human growth hormone of recombinant DNA origin. It stimulates skeletal and soft tissue growth by promoting cell division, amino acid uptake and protein synthesis. It also possesses both insulin-like and diabetogenic effects.
Pharmacokinetics:
Absorption: Well absorbed (SC/IM). Bioavailability ranges from 60-80%.
Metabolism: Renal and hepatic.
Excretion: Via bile. Elimination half-life: 20-30 min (IV), 3-5 hr (SC/IM).

Store at 2-8°C.

Trophic Hormones & Related Synthetic Drugs